PORTON BIOPHARMA

Class [005]
Pharmaceutical and veterinary preparations namely biologics and biopharmaceuticals in the form of vaccines, blood products namely, blood for medical purposes, blood plasma, blood substitutes, reagent blood cells, blood proteins, immunoglobulins and immunomodulatory compounds, therapeutic proteins, gene therapies, and living tissue used to protect against infectious disease namely disorders caused by bacteria, viruses, fungi and parasites and treat cancers, rheumatoid diseases and disorders, skin diseases and disorders namely myeloma and non-melanoma skin cancer and skin infections caused by microbial pathogens, immune system diseases namely autoimmune diseases, immunologic deficiency syndromes, anemia and diseases of the blood namely myelomas, leukaemia and those affecting plasma and white blood cells namely thalassemia, lymphoma, myelodysplastic syndrome, neutropenia, leukocytosis, leukopenia, gastrointestinal diseases and disorders, and neurological diseases namely Alzheimer's, Huntington's Disease, cerebral palsy, Parkinson's disease, multiple sclerosis, cerebrovascular accident (stroke), encephalitis, epilepsy, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, neurodegeneration, amyotrophic lateral sclerosis, peripheral neuropathy, encephalopathy, myasthenia gravis, myopathy, dystonia, spinocerebellar ataxia, demyelinating disease, dysarthria, Guillain-Barré syndrome, chorea, Friedreich's ataxia, polyneuropathy, progressive supranuclear palsy, neuromyelitis optica, motor neurone disease and encephalomyelitis; sanitary preparations for medical purposes namely all purpose disinfectants; materials for dressings namely medical plasters; material for stopping teeth, dental wax; preparations for destroying vermin; fungicides, herbicides; injectable pharmaceutical compositions and preparations comprising compounds having asparaginase activity for the treatment of cancer; pharmaceutical compositions for the treatment of neoplastic conditions namely leukaemia and lymphoma in the blood forming organs